High EE healing rate for TAK-360MR

TAP Pharmaceuticals, a US unit of Japanese drug major Takeda, says that TAK-390MR 60mg and 90mg produced consistently high healing rates for patients with erosive esophagitis. These data were presented at the Digestive Disease Week conference, held in San Diego, USA.

In one study, the life table analysis showed that 93% and 95% of TAK-390MR patients (60mg and 90mg, respectively) experienced healing versus 92% of those on 30mg of another Takeda drug, the heartburn agent Prevacid (lansoprazole). The crude rate analysis showed that 87% of 60mg and 89% of 90mg TAK-390MR patients experienced healing vs 85% of lansoprazole 30mg patients.

In a second study, the life table analysis demonstrated that 92% of both 60mg and 90mg patients experienced healing vs 86% of patients on lansoprazole 30mg. The crude rate evaluation showed that 85% and 86% of patients treated with TAK-390MR (60mg and 90mg, respectively) experienced healing vs 79% of subjects taking lansoprazole 30mg. The results for TAK-390MR 90mg were statistically significantly higher than lansoprazole 30mg in both studies using crude rate analysis.